Key Takeaways

  • Q1 adjusted earnings per share reached $7.79, surpassing analyst expectations of $7.60
  • Total revenue climbed 5% to $68.5 billion, exceeding the projected $66.3 billion
  • Management increased 2026 full-year EPS forecast to a minimum of $30.35, representing a $0.10 uplift
  • Shares declined approximately 3% following the earnings announcement due to pharmacy benefit concerns
  • David Cordani will retire as CEO effective July 1, with COO Brian Evanko assuming leadership

Cigna delivered a robust first-quarter performance that failed to win over Wall Street. The health insurance giant exceeded earnings and revenue projections while raising its annual forecast, yet shares moved lower.

Adjusted earnings per share for the quarter reached $7.79, representing growth from $6.74 in the prior-year period and beating the analyst consensus of $7.60. Total revenue touched $68.5 billion, marking a 5% year-over-year expansion and surpassing the anticipated $66.3 billion.

Management elevated its 2026 full-year EPS projection to a minimum of $30.35, reflecting a $0.10 boost from earlier guidance. This updated midpoint marginally exceeds the Street consensus of $30.33.


CI Stock Card
Cigna Corporation, CI

Shares retreated roughly 3% to approximately $283 during morning trading hours despite these positive metrics.

Adjusted operational income advanced 12% to $2.1 billion versus $1.8 billion during the first quarter of 2025. This growth stemmed from contributions across Cigna Healthcare and Evernorth Health Services segments.

Cigna Healthcare’s pre-tax adjusted operational income surged 18% to $1.5 billion. The segment’s medical care ratio showed improvement at 79.8%, compared to 82.2% in the corresponding quarter last year.

Evernorth posted adjusted revenues of $58.4 billion, representing 9% year-over-year growth. Income from Specialty and Care Services rose 20% to $1.1 billion.

Pharmacy Segment Raises Concerns

The pharmacy benefit manager division presented challenges. TD Cowen analyst Charles Rhyee identified it as the “only blemish” in an otherwise strong quarterly report, though he emphasized this came as expected given comparable struggles at UnitedHealth and Elevance Health. Rhyee maintained a Buy rating with a $338 target price.

Leerink Partners analyst Whit Mayo maintained a Market Perform rating, stating the results “look fine” while noting that “not much jumps off the page as particularly surprising.”

Cigna has undertaken a strategic transformation of its PBM operations since autumn, transitioning toward a “rebate-free” framework in response to regulatory scrutiny and public concerns surrounding drug pricing transparency.

Management Change Creates Additional Questions

This past February, Cigna’s Express Scripts division became the first among the three dominant PBMs to reach a settlement with the Federal Trade Commission regarding insulin pricing litigation. The company admitted no wrongdoing, and the settlement terms aligned with the previously announced rebate-free approach.

A major leadership transition looms for the organization. CEO David Cordani plans to retire effective July 1, with COO Brian Evanko promoted to the chief executive position.

The convergence of an evolving business model, executive succession, and measured analyst sentiment provides context for why a quarter featuring both a beat and raised guidance failed to drive shares higher.

The improved medical care ratio alongside organic expansion in specialty service lines represented the most encouraging aspects of the quarterly performance.